Susquehanna International Group
VIRX

Susquehanna International Group’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Susquehanna International Group’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-15,300
Closed -$22.3K – 13677
2022
Q4 		$22.3K Sell
15,300
-56,800
-79% -$166K ﹤0.01% 11730
2022
Q3 		$308K Sell
72,100
-19,500
-21% -$82.6K ﹤0.01% 9735
2022
Q2 		$355K Buy
91,600
+8,700
+10% +$24.8K ﹤0.01% 9107
2022
Q1 		$395K Buy
82,900
+60,600
+272% +$183K ﹤0.01% 9576
2021
Q4 		$81K Sell
22,300
-4,500
-17% -$24K ﹤0.01% 12278
2021
Q3 		$215K Sell
26,800
-14,300
-35% -$141K ﹤0.01% 11340
2021
Q2 		$466K Buy
41,100
+1,400
+4% +$14K ﹤0.01% 9755
2021
Q1 		$367K Buy
39,700
+28,414
+252% +$296K ﹤0.01% 10182
2020
Q4 		$79K Sell
11,286
-3,714
-25% -$19.4K ﹤0.01% 10602
2020
Q3 		$66K Buy
15,000
+13,311
+788% +$116K ﹤0.01% 10112
2020
Q2 		$16K Sell
1,689
-911
-35% -$13.7K ﹤0.01% 9946
2020
Q1 		$38K Buy
2,600
+491
+23% +$10.7K ﹤0.01% 9770
2019
Q4 		$25K Sell
2,109
-31
-1% -$519 ﹤0.01% 9466
2019
Q3 		$54K Buy
2,140
+843
+65% +$24.3K ﹤0.01% 9752
2019
Q2 		$33K Buy
1,297
+988
+320% +$38.2K ﹤0.01% 9923
2019
Q1 		$13K Sell
309
-1,160
-79% -$26.3K ﹤0.01% 8638
2018
Q4 		$21K Sell
1,469
-794
-35% -$32.4K ﹤0.01% 8673
2018
Q3 		$158K Sell
2,263
-191
-8% -$14.5K ﹤0.01% 8388
2018
Q2 		$182K Buy
2,454
+340
+16% +$30.3K ﹤0.01% 8698
2018
Q1 		$201K Buy
2,114
+1,540
+268% +$264K ﹤0.01% 8321
2017
Q4 		$74K Sell
574
-640
-53% -$60K ﹤0.01% 8803
2017
Q3 		$82K Sell
1,214
-432
-26% -$35.3K ﹤0.01% 8425
2017
Q2 		$156K Buy
1,646
+566
+52% +$65K ﹤0.01% 8473
2017
Q1 		$155K Buy
1,080
+211
+24% +$30.2K ﹤0.01% 8177
2016
Q4 		$110K Buy
869
+212
+32% +$29.5K ﹤0.01% 9035
2016
Q3 		$101K Buy
657
+534
+434% +$75.4K ﹤0.01% 7935
2016
Q2 		$14K Buy
123
+5
+4% +$554 ﹤0.01% 8408
2016
Q1 		$13K Sell
118
-526
-82% -$79.7K ﹤0.01% 8859
2015
Q4 		$121K Sell
644
-320
-33% -$59.9K ﹤0.01% 8791
2015
Q3 		$164K Sell
964
-2,697
-74% -$973K ﹤0.01% 8858
2015
Q2 		$2.31M Buy
3,661
+2,163
+144% +$1.15M ﹤0.01% 4402
2015
Q1 		$771K Buy
1,498
+974
+186% +$491K ﹤0.01% 6275
2014
Q4 		$281K Sell
524
-4,756
-90% -$2.14M ﹤0.01% 8238
2014
Q3 		$7.92M Buy
5,280
+1,957
+59% +$2.83M ﹤0.01% 2382
2014
Q2 		$4.55M Buy
3,323
+356
+12% +$413K ﹤0.01% 3248
2014
Q1 		$4.12M Buy
2,967
+2,691
+975% +$3.13M ﹤0.01% 3167
2013
Q4 		$274K Buy
+276
New +$285K ﹤0.01% 7731

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group's VIRX Position: Q1 2024 in Review

Susquehanna International Group sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2024, closing a stake of 41,412 shares — an estimated $23.6K sold.

Susquehanna International Group first reported a position in VIRX in Q2 2013 and held it in 25 quarters. The position peaked at $1.72M in Q1 2015. 40 funds tracked by Wall St. Rank hold VIRX as of Q1 2024.

  • Susquehanna International Group reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Susquehanna International Group sold 41,412 Viracta Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $23.6K.
  • Susquehanna International Group first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 25 quarters.
  • Susquehanna International Group's Viracta Therapeutics, Inc. Common Stock position peaked at $1.72M in Q1 2015.
  • 40 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Susquehanna International Group's 13F filing for Q1 2024, filed 7 May 2024.